FN2 Earnings Intelligence
Abbott Laboratories balance sheet (quarterly)
Abbott Laboratories (ABT) Balance Sheet (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $7,558 | $6,532 | $6,951 | $7,511 | $6,803 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $10,635 | $10,358 | $11,142 | $11,369 | $11,164 | $12,519.5 | $12,993.1 |
| % Growth | - | - | - | - | - | 12.4% | 14.3% |
| Gross Profit | $5,937 | $5,890 | $6,288 | $6,294 | $6,274 | - | - |
| % Margin | 55.8% | 56.9% | 56.4% | 55.4% | 56.2% | - | - |
| EBITDA | - | $2,029 | $2,409 | $2,428 | $1,726 | - | - |
| % Margin | - | 19.6% | 21.6% | 21.4% | 15.5% | - | - |
| Net Income | $1,646 | $1,325 | $1,779 | $1,644 | $1,077 | - | - |
| % Margin | 15.5% | 12.8% | 16.0% | 14.5% | 9.6% | - | - |
| Diluted EPS | $0.94 | $0.76 | $1.01 | $0.94 | $0.61 | $1.28 | $1.42 |
| % Growth | - | - | - | - | - | 26.5% | 50.8% |
| Operating Cash Flow | - | $1,417 | - | - | $1,315 | - | - |
| CapEx | - | $484 | - | - | $399 | - | - |
| Free Cash Flow | - | $933 | - | - | $916 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $10,635 | $10,358 | $11,142 | $11,369 | $11,164 | $12,519.5 | $12,993.1 |
| Gross Profit | $5,937 | $5,890 | $6,288 | $6,294 | $6,274 | - | - |
| EBITDA | - | $2,029 | $2,409 | $2,428 | $1,726 | - | - |
| Net Income | $1,646 | $1,325 | $1,779 | $1,644 | $1,077 | - | - |
| Diluted EPS | $0.94 | $0.76 | $1.01 | $0.94 | $0.61 | $1.28 | $1.42 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $7,558 | $6,532 | $6,951 | $7,511 | $6,803 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $12,825 | $12,736 | $12,930 | $11,596 | $29,638 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | $1,417 | - | - | $1,315 |
| Capital Expenditure | - | $484 | - | - | $399 |
| Free Cash Flow | - | $933 | - | - | $916 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 55.8% | 56.9% | 56.4% | 55.4% | 56.2% |
| EBITDA Margin | - | 19.6% | 21.6% | 21.4% | 15.5% |
| Net Margin | 15.5% | 12.8% | 16.0% | 14.5% | 9.6% |
| FCF Margin | - | 9.0% | - | - | 8.2% |
| Diluted EPS Growth | - | - | - | - | - |